Evidence map›Paper›PMID 35242673›Full record

ArticleGland surgery2022

Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in

Ying Wen, Dengjie Ouyang, Qitong Chen, Liyun Zeng, Na Luo, Hongye He, Munawar Anwar, Limeng Qu, Qiongyan Zou, Wenjun Yi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gland surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ying Wen *Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Dengjie Ouyang *Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Qitong ChenDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Liyun ZengDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Na LuoDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Hongye HeDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Munawar AnwarDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Limeng QuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Qiongyan ZouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Wenjun YiDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNSecond Xiangya Hospital of Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether tumor mutation burden (TMB) correlated with improved survival outcomes or promotion of immunotherapies remained controversy in various malignancies. We aimed to explore the prognostic value of TMB and the relationship between TMB and immune infiltration in

methodsWe downloaded somatic mutation data and clinical information for 216

resultsTMB was negatively correlated with overall survival (OS) and disease-free survival (DFS), and high TMB may inhibit immune infiltration in

conclusionsHigher TMB correlated with poor survival outcomes and might inhibit the immune infiltrates in

Indexed as

HER2+ breast cancer (HER2+ BC)immune infiltrationprognostic modeltumor mutation burden (TMB)

Identifiers

PMID35242673
PMCPMC8825527
OpenAlexW4206178890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.